Natera, Inc. NTRA 深 沪
交易中 04-01 10:43:35 美东时间
204.435
+4.445
+2.22%
华盛通- 最 高205.00
- 今 开201.00
- 成交量 22.28万股
- 最 低 199.655
- 昨 收 199.99
- 总市值 289.75亿
- 52周最高 256.36
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 131.8106
- 委 比 -81.82%
- 总股本 1.42亿
- 历史最高 256.36
- 量 比 1.56
- 振 幅 2.67%
- 历史最低 6.52
- 每 手 1
- 风险率 32.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery
Natera Signatera data shows MRD-guided therapy may reduce surgery in older breast cancer patients; analysts maintain bullish outlook.
今天 00:48
If You Invested $1000 In Natera Stock 10 Years Ago, You Would Have This Much Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 24.2...
03-25 23:00
Natera Announced Two Peer-reviewed Publications Highlighting Clinical Utility Of Signatera, Its Personalized, Tumor-informed Circulating Tumor DNA Assay, In Anal Squamous Cell Carcinoma And Locally Advanced Rectal Cancer
ASCC: publication in Nature CommunicationsA recently published study evaluated 84 patients with ASCC to assess whether serial Signatera testing may offer a dynamic, treatment-responsive biomarker to further stratify
03-16 18:15
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Natera To Present New Data In Genitourinary Malignancies At ASCO GU 2026
11 scientific abstracts, including 4 oral presentations and a concurrent publication in Nature Medicine, underscore how Signatera MRD can improve quality of life for patients with genitourinary cancersNatera, Inc.
02-27 23:06
Forecasting The Future: 10 Analyst Projections For Natera
In the last three months, 10 analysts have published ratings on Natera (NASDAQ:...
02-27 21:01
Baird Maintains Outperform on Natera, Raises Price Target to $257
Baird analyst Catherine Ramsey maintains Natera (NASDAQ:NTRA) with a Outperform and raises the price target from $239 to $257.
02-27 20:56
财报速睇 | Natera, Inc. 2025财年年度营收23.06亿美元，同比增长35.9%；归母净利润亏损2.08亿美元，同比亏损扩大9.5%
华盛资讯2月27日讯，Natera, Inc.公布2025财年年度业绩，公司年度营收23.06亿美元，同比增长35.9%，归母净利润亏损2.08亿美元，同比亏损扩大9.5%。
02-27 20:02
电话会总结 ｜ Natera(NTRA)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Natera业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2025年Q4营收达到6.66亿美元，较预告高出约600万美元，同比增长约40%。全年现金流超过1.07亿美元。 **利润率水平：** Q4毛利率达到66.9%，创历史新高。其中约3%（6000万美元）来自收入调整，剔除调整后的有机毛利率为63.7%，较Q3环比提升240个基点。2025年全年剔除调整后毛利率约为61.5%。 **运营表现：** Q4运营亏损较去年同期显著收窄，尽管运营支出大幅增加。Q4实现净利润，但主要受益于与Foresight收购相关的
02-27 12:16
